Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Retained Earnings (2016 - 2025)

IGC Pharma has reported Retained Earnings over the past 15 years, most recently at -$4.9 million for Q3 2025.

  • Quarterly Retained Earnings rose 95.88% to -$4.9 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$4.9 million through Sep 2025, up 95.88% year-over-year, with the annual reading at -$120.7 million for FY2025, 6.23% down from the prior year.
  • Retained Earnings was -$4.9 million for Q3 2025 at IGC Pharma, down from -$3.5 million in the prior quarter.
  • Over five years, Retained Earnings peaked at -$2.8 million in Q1 2021 and troughed at -$120.7 million in Q1 2025.
  • The 5-year median for Retained Earnings is -$4.9 million (2025), against an average of -$49.3 million.
  • Year-over-year, Retained Earnings plummeted 3114.1% in 2022 and then skyrocketed 96.46% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$82.7 million in 2021, then decreased by 16.91% to -$96.6 million in 2022, then skyrocketed by 96.46% to -$3.4 million in 2023, then dropped by 0.99% to -$3.5 million in 2024, then plummeted by 40.33% to -$4.9 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Retained Earnings are -$4.9 million (Q3 2025), -$3.5 million (Q2 2025), and -$120.7 million (Q1 2025).